People · Operator
Named in public records as an officer, director or promoter · active 2011–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc | — | Pharmaceuticals | Series C | $97.5M | $701.8M | 2015 |
| SpringLeaf Therapeutics, Inc. | — | Pharmaceuticals | Series B | $34.1M | $647.7M | 2011 |
Garen Bohlin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Garen Bohlin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Hirsch | 1 | 16 |
| Michael Greeley | 1 | 15 |
| Brian Gallagher | 1 | 11 |
| Patrick Heron | 1 | 11 |
| Stephen Hoffman | 1 | 7 |
| John Freund | 1 | 7 |
| Jeffrey McCarthy | 1 | 7 |
| Gino Santini | 1 | 5 |
| Kurt Graves | 1 | 5 |
| Michael Heffernan | 1 | 5 |
| Michael Cima | 1 | 4 |
| Paul Brannelly | 1 | 4 |
| Eran Nadav | 1 | 4 |
| Yet-Ming Chiang | 1 | 3 |
| Steven N. Tannenbaum | 1 | 3 |
| Patrick N. Heron | 1 | 3 |
| Gino W. Santini | 1 | 3 |
| Theodore A Schroeder | 1 | 2 |
| Stephen W. Hoffman | 1 | 2 |
| Patrick Fortune | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.